Company profile

Yuhan Corporation

Diversified pharma

Public Market Listing

000100KRX

KRX primary exchange listing

Live quotes, historical charts, and market capitalization for Yuhan Corporation are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(9 total)

9Total Assets

1Approved

3Phase 3 / Filed

5Phase 1–2 / Early

2Diseases

Showing 9 of 9 assets

		Target & Modality
Lazertinib	Approved	EGFRSmall molecule	Non-Small Cell Lung Cancer
Anplag tabNo recent activity	Phase 3	Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule	Atherosclerotic Cardiovascular Disease
rosuvastatin/ezetimibe	Phase 3	HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinalSmall molecule	Atherosclerotic Cardiovascular Disease
Sarpogrelate(Anplag)	Phase 3	5-HT2A receptorSmall molecule	Atherosclerotic Cardiovascular Disease
YH32364	Phase 2	EGFR x 4-1BB (CD137)Small molecule	Non-Small Cell Lung Cancer
YH42946	Phase 2	HER2 exon 20 insertions; EGFR exon 20 insertionsSmall molecule	Non-Small Cell Lung Cancer
Monorova(Gemigliflozin)	Preclinical	SGLT2Small molecule	Atherosclerotic Cardiovascular Disease
Rosuampin(Rosuampin)No recent activity	Preclinical	HMG-CoA reductase / Calcium channelSmall molecule	Atherosclerotic Cardiovascular Disease
Rosuvamibe	Preclinical	HMG-CoA reductase / NPC1L1Small molecule	Atherosclerotic Cardiovascular Disease

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.